| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
701.66(B) |
| Last
Volume: |
2,008,266 |
Avg
Vol: |
3,289,637 |
| 52
Week Range: |
$390.35 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
644,570 |
871,420 |
3,176,506 |
6,211,418 |
| Total Sell Value |
$465,524,857 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
8 |
14 |
47 |
89 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-05-15 |
4 |
AS |
$435.29 |
$261,174 |
D/D |
(600) |
5,978 |
|
27% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-05-12 |
4 |
S |
$442.25 |
$9,141,436 |
D/D |
(20,646) |
101,668,164 |
|
-27% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-05-03 |
4 |
S |
$415.72 |
$76,028,738 |
D/D |
(178,302) |
101,688,810 |
|
-39% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-05-02 |
4 |
S |
$408.72 |
$17,085,592 |
D/D |
(41,698) |
101,867,112 |
|
-47% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-04-28 |
4 |
S |
$395.36 |
$89,657,657 |
D/D |
(225,000) |
101,908,810 |
|
-45% |
|
| Johnson Kimberly H |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$9,681 |
D/D |
26 |
2,072 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$4,841 |
D/D |
13 |
1,648 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$10,053 |
D/D |
27 |
70,949 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$1,862 |
D/D |
5 |
63,524 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$10,053 |
D/D |
27 |
930 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$11,171 |
D/D |
30 |
53,025 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$14,522 |
D/D |
39 |
14,918 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-04-06 |
4 |
S |
$364.98 |
$47,853,821 |
D/D |
(130,297) |
102,133,810 |
|
-48% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-04-05 |
4 |
S |
$363.24 |
$25,327,917 |
D/D |
(69,703) |
102,264,107 |
|
-51% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-03-24 |
4 |
S |
$335.75 |
$67,164,555 |
D/D |
(200,000) |
102,748,810 |
|
-34% |
|
| Johnson Kimberly H |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$9,674 |
D/D |
29 |
2,046 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$5,004 |
D/D |
15 |
1,635 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$11,342 |
D/D |
34 |
52,995 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$10,008 |
D/D |
30 |
655 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$10,008 |
D/D |
30 |
70,922 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$2,002 |
D/D |
6 |
63,519 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$14,345 |
D/D |
43 |
14,879 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-03-10 |
4 |
AS |
$318.85 |
$318,850 |
D/D |
(1,000) |
8,908 |
|
47% |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2023-03-01 |
4 |
D |
$311.22 |
$262,358 |
D/D |
(843) |
26,861 |
|
- |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,890 |
27,704 |
|
- |
|
1437 Records found
|
|
Page 7 of 58 |
|
|
8.64 (1.19%) 
